ZHONGSHENGYAOYE(SZ:002317) Xin Lang Cai Jing·2025-05-23 08:33Core Viewpoint - The approval of Angladevir tablets marks a significant breakthrough for the company in the innovative drug sector, with potential for rapid market penetration in the billion-level influenza market [2][3]. Group 1: Product Approval and Clinical Data - Angladevir tablets, developed by the company's subsidiary, have received approval from the National Medical Products Administration for the treatment of adult uncomplicated influenza [1]. - The Phase III clinical trial results indicate that Angladevir significantly outperformed the placebo group in key endpoints, including the time to relief of seven influenza symptoms [2]. - The company is also developing a granule formulation of Angladevir for children and adolescents aged 2-17, with promising Phase II trial results showing shorter symptom relief times compared to adult data [2]. Group 2: Market Potential - The influenza drug market in China exceeded 10 billion yuan in 2023 and is projected to reach 22.39 billion yuan by 2027 [3]. - Current leading antiviral drugs include Oseltamivir and Marbofloxacin, with Oseltamivir sales exceeding 8 billion yuan in 2023 [3]. - Angladevir, as a PB2-targeting RNA polymerase inhibitor, shows superior efficacy against various influenza strains compared to existing treatments, including those resistant to Oseltamivir and Marbofloxacin [3]. Group 3: Financial Forecast - The company anticipates accelerated revenue growth following the commercialization of Angladevir, projecting revenues of 2.765 billion yuan, 3.216 billion yuan, and 3.774 billion yuan for 2025-2027 [9]. - Expected net profits for the same period are 300 million yuan, 391 million yuan, and 517 million yuan, with corresponding EPS of 0.35 yuan, 0.46 yuan, and 0.61 yuan [9].